NXP 900
Alternative Names: eCF506; NXP-900Latest Information Update: 08 Aug 2024
At a glance
- Originator University of Edinburgh
- Developer Nuvectis Pharma; University of Edinburgh
- Class Antineoplastics; Carbamates; Piperidines; Pyrazoles; Pyrimidines; Small molecules
- Mechanism of Action Proto-oncogene protein c-yes inhibitors; Src-family kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Squamous cell cancer
Most Recent Events
- 06 Aug 2024 Nuvectis Pharma plans a clinical trial for Non-small cell lung cancer (Second-line therapy or greater, Combination therapy, Late-stage disease)
- 08 Apr 2024 Pharmacodynamics data from a preclinical study in Non-small cell lung cancer released by Nuvectis Pharma
- 05 Apr 2024 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)